This report was first published by Endpoints News. To see the original version, click here
The US government said it will refer telehealth and GLP-1 company Hims & Hers to the Department of Justice for investigation, following the company’s controversial launch of a compounded version of Novo Nordisk’s newly approved weight loss pill.
On Friday afternoon, HHS General Counsel Mike Stuart posted to X that his office had referred the company for potential violations of the Federal Food, Drug, and Cosmetic Act, which regulates drug compounding.
您已阅读20%（544字），剩余80%（2182字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。